Market closedNon-fractional
Rocket Pharmaceuticals/RCKT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Rocket Pharmaceuticals
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis.
Ticker
RCKT
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Cranbury, United States
Employees
268
Website
www.rocketpharma.com
RCKT Metrics
BasicAdvanced
$2.3B
Market cap
-
P/E ratio
-$2.85
EPS
1.11
Beta
-
Dividend rate
Price and volume
Market cap
$2.3B
Beta
1.11
Financial strength
Current ratio
10.473
Quick ratio
10.283
Long term debt to equity
5.227
Total debt to equity
5.084
Interest coverage (TTM)
-141.02%
Management effectiveness
Return on assets (TTM)
-32.64%
Return on equity (TTM)
-55.38%
Valuation
Price to book
5.3
Price to tangible book (TTM)
6.2
Price to free cash flow (TTM)
-10.804
Growth
Earnings per share change (TTM)
-13.69%
3-year earnings per share growth (CAGR)
1.54%
What the Analysts think about RCKT
Analyst Ratings
Majority rating from 15 analysts.
RCKT Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$62M
4.03%
Profit margin
0.00%
NaN%
RCKT Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.82
-$0.75
-$0.64
-$0.66
-
Expected
-$0.79
-$0.81
-$0.79
-$0.68
-$0.72
Surprise
3.80%
-7.23%
-18.56%
-3.06%
-
RCKT News
AllArticlesVideos
FDA Again Delays Approval of Rocket Pharmaceuticals' Gene Therapy Treatment
Investopedia·4 weeks ago
Rocket Pharmaceuticals Provides Regulatory Update on KRESLADI™ (marnetegragene autotemcel; marne-cel)
Business Wire·4 weeks ago
Rocket Pharmaceuticals Receives Orphan Medicinal Product Designation from the European Commission for RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Rocket Pharmaceuticals stock?
Rocket Pharmaceuticals (RCKT) has a market cap of $2.3B as of July 27, 2024.
What is the P/E ratio for Rocket Pharmaceuticals stock?
The price to earnings (P/E) ratio for Rocket Pharmaceuticals (RCKT) stock is 0 as of July 27, 2024.
Does Rocket Pharmaceuticals stock pay dividends?
No, Rocket Pharmaceuticals (RCKT) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Rocket Pharmaceuticals dividend payment date?
Rocket Pharmaceuticals (RCKT) stock does not pay dividends to its shareholders.
What is the beta indicator for Rocket Pharmaceuticals?
Rocket Pharmaceuticals (RCKT) has a beta rating of 1.11. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Rocket Pharmaceuticals stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.